Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
Open Access
- 15 January 2021
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 8 (1) , e000827
Abstract
Background Non-invasive biomarkers for the assessment of disease severity in idiopathic pulmonary fibrosis (IPF) are urgently needed. Calprotectin belongs to the S-100 proteins produced by neutrophils, which likely contribute to IPF pathogenesis. Calprotectin is a well-established biomarker in inflammatory bowel diseases. In this cross-sectional study, we aimed to establish the potential role of calprotectin as a biomarker in IPF. Specifically, we hypothesised that patients with IPF have higher serum calprotectin levels compared with healthy controls, and that calprotectin levels are associated with disease severity. Methods Blood samples were obtained from healthy volunteers (n=26) and from two independent IPF cohorts (derivation cohort n=26, validation cohort n=66). Serum calprotectin levels were measured with a commercial kit adapted for that purpose and compared between healthy controls and patients with IPF. Clinical parameters, including forced vital capacity, diffusing capacity for carbon monoxide (DLCO) and the Composite Physiologic Index (CPI), were correlated with calprotectin serum levels. Results The IPF derivation cohort showed increased serum calprotectin levels compared with healthy controls (2.47±1.67 vs 0.97±0.53 µg/mL, pConclusion Serum calprotectin levels are significantly increased in patients with IPF compared with healthy controls and correlate with DLCO and CPI. Calprotectin might be a potential new biomarker for disease severity in IPF.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/00367)
- Centro de Investigación Biomédica en Red (Not applicable)
- Boehringer Ingelheim (Not applicable)
- F. Hoffmann-La Roche (Not applicable)
This publication has 38 references indexed in Scilit:
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosisRespiratory Medicine, 2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseasesClinical and Experimental Immunology, 2010
- Calgranulin B (S100A9/MRP14): A Key Molecule in Idiopathic Pulmonary Fibrosis?Inflammation, 2010
- Emerging Concepts in the Pathogenesis of Lung FibrosisThe American Journal of Pathology, 2009
- Baseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary FibrosisChest, 2008
- S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern moleculesJournal of Leukocyte Biology, 2006
- The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responsesJournal of Clinical Investigation, 2001
- The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responsesJournal of Clinical Investigation, 2001